This trial is active, not recruiting.

Condition esophageal cancer
Treatments irinotecan, cisplatin, radiation, surgery, sunitinib (sutent)
Phase phase 2
Sponsor University Health Network, Toronto
Collaborator Pfizer
Start date November 2006
End date December 2016
Trial size 36 participants
Trial identifier NCT00400114, 06-0407-C


The purpose of this study is to see whether or not the combination of cisplatin, irinotecan and radiation, followed by surgery, followed by oral Sutent, is effective and safe for patients with resectable esophageal cancer.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Irinotecan (50mg/m2)once weekly in weeks 1, 2, 4, 5, 7, and 8
Cisplatin (65mg/m2)once weekly in weeks 1, 2, 4, 5, 7, and 8
Radiation 50 Gy (weeks 4-9)
sunitinib (sutent)
sunitinib (Sutent), dose range of 12.5mg - 50mg OD x 1 year post op.

Primary Outcomes

To determine the feasibility and efficacy of adjuvant Sutent therapy after concurrent neoadjuvant therapy with Irinotecan, Cisplatin, external beam conformal radiotherapy plus surgery for potentially resectable esophageal cancer.
time frame: 5 yrs

Secondary Outcomes

To assess the impact of adjuvant targeted therapy with Sutent after multimodality therapy for resected esophageal cancer stage II to III, and to compare these data to our current completed trial in the same patient population
time frame: 5 yrs
To characterize toxicity of targeted adjuvant therapy with Sutent after multimodality therapy for resected esophageal cancer stage II to III
time frame: 2 yrs
To measure time-to-event efficacy variables including: Time to treatment failure and Time to progressive disease
time frame: 5 yrs
Survival of patients with esophageal cancer stage II to III with adjuvant targeted therapy added to multimodality treatment protocol
time frame: 5 yrs
To determine the pattern of relapse (local versus distant) with the addition of adjuvant targeted therapy to esophageal cancer multimodality therapy
time frame: 5 yrs

Eligibility Criteria

Male or female participants from 18 years up to 70 years old.

Inclusion Criteria: - Histologically proven squamous or adenocarcinoma or the esophagus >20 cm from the incisors, including GE junction tumors (unless of gastric origin). - Tumors must be technically resectable. - Clinical T1N1M0, T2-3 N0-1 M0 - Performance status ECOG 0-1 - Medically fit for chemotherapy, radiation and esophagectomy Exclusion Criteria: - In situ or clinical T1N0M0, and stage IV (M1a orM1b) - Cervical esophageal tumors (within 20 cm of the incisors) - Age <18 or >70 - Participation in another concurrent clinical study involving study drug(s) or treatment with study drug within thirty days prior to the treatment on this study. Concurrent treatment with other experimental drugs or anticancer therapy - known or suspected drug or alcohol abuse - Prior treatment for this malignancy except esophageal stenting

Additional Information

Official title Adjuvant Sutent Following Chemotherapy, Radiation and Surgery For Esophageal Cancer, A Phase II Trial (ASSET)
Principal investigator Jennifer J Knox, MD M.Sc. FRCPC
Description Survival outcomes for resectable esophageal cancer remain poor. Current data strongly support an adjuvant systemic strategy to improve time to progression and survival in this patient population. Adding a well-tolerated oral targeted therapy such as Sutent, after a combined chemo/radiation/surgery approach in this patient population has the potential to impact on the minimal residual disease left behind by relatively effective pre-operative chemoradiation and surgery. This has the potential to improve survival. The primary endpoint is to determine the feasibility and efficacy of adjuvant Sutent therapy (SU11248) after concurrent neoadjuvant therapy with irinotecan, cisplatin, external beam conformal radiotherapy plus surgery for potential resectable esophageal cancer. Preclinical and clinical data suggest that Sutent will have activity in esophageal cancer, as the results of Sutent activity in solid tumors appear to be superior to the results of other antiangiogenic compounds in development for esophageal cancer. Therefore, by extrapolation from promising phase I, II and III Sutent trials we propose to translate the target effects achieved with Sutent to reduce local and systemic therapy failure, and thus metastasis in esophageal cancer.
Trial information was received from ClinicalTrials.gov and was last updated in March 2016.
Information provided to ClinicalTrials.gov by University Health Network, Toronto.